Imperial College London
Alternate

Professor Paul D. Lickiss

Faculty of Natural Sciences, Department of Chemistry

Senior Research Investigator
 
 
 
//

Contact

 

+44 (0)20 7594 5761p.lickiss Website

 
 
//

Location

 

601DMolecular Sciences Research HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Mohamed:2016:10.11159/nddte16.113,
author = {Mohamed, NA and Davies, R and Lickiss, PD and Freeman, G and Morales-Cano, D and Barreira, B and Kirkby, NS and Moreno, L and Mitchell, JA},
doi = {10.11159/nddte16.113},
title = {In Vivo Assessment of Metal Organic Framework (MOFs) for the Future use as Delivery Agents for Drugs to Treat PAH},
url = {http://dx.doi.org/10.11159/nddte16.113},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AB  - Pulmonary arterial hypertension (PAH) is a progressive, debilitating and fatal condition with no cure. However small molecule drugs, including sildenafil, selexipag and bosentan, have been developed and are used to treat PAH but do not offer a cure and life expectancy, even on medication, is only between 2-5 years after diagnosis. All PAH drugs are ubiquitous dilators and their therapeutic dose is severely limited by their systemic side-effects [1]. We are working on the hypothesis that current PAH-drugs could be used more effectively at higher local (to the lung) concentrations if delivered selectively using a nanomedicine approach. We suggest that if toxicological limitations of nanomedicines can be overcome their use in PAH to delivery current drugs to the lung could turn this fatal disease to a chronic drug-managedcondition. One nanoparticle that we are interested in is from the Materials of Institute Lavoisier (MIL), the so called MIL-89. MIL-89 is an iron based metal organic framework (MOF). MIL-89 is a good candidate for delivery of drugs because (i) it can be tailored to accommodate different drugs including those with the molecular weights of current PAH-medications (MW; 300-500) [2], (ii) it is biocompatible and biodegradable [3]; (iii) it has a large internal surface area and high drug loading capacity; (iv) it is thermally and mechanically stable; and (v) it promises a long drug release-period with the ability to incorporate different functional groups [2, 4-5]. We have previously shown that MIL-89 at concentrations up to 10µg/ml is non-toxic to human lung cells including those from patients with PAH. In the current study we have investigated the effects of MIL-89 in rats in vivo for markers of toxicity. MIL-89 at 50mg/kg was administered (i.p.) for two weeks at days 0, 1, 3, 7, 10 and 14. At each time point rats were weighed, killed, plasma and tissues collected. MIL-89 had no effect on body weight, lung oedema or on plasma markers of organ failur
AU  - Mohamed,NA
AU  - Davies,R
AU  - Lickiss,PD
AU  - Freeman,G
AU  - Morales-Cano,D
AU  - Barreira,B
AU  - Kirkby,NS
AU  - Moreno,L
AU  - Mitchell,JA
DO  - 10.11159/nddte16.113
PY  - 2016///
TI  - In Vivo Assessment of Metal Organic Framework (MOFs) for the Future use as Delivery Agents for Drugs to Treat PAH
UR  - http://dx.doi.org/10.11159/nddte16.113
ER  -
Download